Spotlight – KRS: A cut away from release in exosomes

JCB

KRS: A cut away from release in exosomes

 
Catherine Rabouille

Cancer cells often trigger an inflammatory process, which in some cases may be driven by the presence of lysyl-tRNA synthetase (KRS) in the medium. Kim et al. (2017. J. Cell Biol.https://doi.org/10.1083/jcb.201605118) now demonstrate that cleavage of the KRS by caspase-8 inside cells triggers its interaction with syntenin and its release in inflammatory exosomes.

Aminoacyl-tRNA synthetases (ARSs) are intriguing enzymes. Intracellularly, they catalyze the covalent attachment of amino acids to tRNAs and are key regulators of protein translation. However, these housekeeping enzymes have many other tricks up their sleeves. In the cell, several ARSs are also able to regulate gene expression at the level of transcription, splicing, and translation but via noncatalytic and unique mechanisms. ARSs also have different functions in the extracellular space, where they can elicit cytokine signaling responses that control angiogenesis, induce immune and proinflammatory gene expression programs, and trigger cell migration or apoptosis. The response elicited by particular ARSs is specific to the target cells (Son et al., 2014). For instance, when present in the extracellular medium, lysyl-tRNA synthetase (KRS) binds to macrophages and monocytes and activates MAPK signaling pathways that induce macrophage migration and TNF production (Park et al., 2005). How ARSs are released to the extracellular medium to carry out these activities is unknown. ARSs do not contain a signal peptide, and pharmacological agents blocking secretion through the secretory pathway have no effect on the amount of ARS in the medium. For a while, the presence of ARSs in the extracellular medium was thus thought to be caused by their passive release from cells that have undergone necrosis. In this issue, Kim et al. reinvestigate how KRS is released from cancer cells and find that this occurs through a caspase-8– and syntenin-dependent incorporation of KRS in exosomes.

http://jcb.rupress.org/content/early/2017/06/15/jcb.201706039

Related Post

A paper on a new ARS receptor was published in the...
views 243
Dr. Hyuck Sang Kwon's article was published in the Journal of Cell Science for discovering  a new AIMP1 receptor.   The title of the article...
의약바이오컨버젼스연구단 연구원 채용...
views 301
<서울대학교 의약바이오컨버젼스연구단 연구원 채용>미래창조과학부 글로벌프론티어 연구개발사업의 일환으로, 혁신을 통하여 신약개발의 새로운 파라다임을 제시하고자 출범한 서울대학교 의약바이오컨버젼스연구단에서 아래와 같은 업무를 수행할 수 있는 성실하고 책임감있는 연...
이진영 박사과정, AARS 2013 Oral Presentation Award 수상...
views 245
연구단 이진영 박사과정 학생이 10월 6일~11일 일본 하코네에서 열린 AARS 2013에서 Oral Presentation Award를 수상하였습니다.발표 제목은 Methionyl-tRNA Synthetase-mediated Misacylation as a ...
Top Biotech Trends for 2017
views 878
Top Biotech Trends for 2017 What key trends could propel biotech forward in 2017? No doubt about it—2016 was a tumultuous year for biotech. But that...

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2010-2018 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?

Skip to toolbar